Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced RashResearch Question:
What are the side effects of ketoconazole and how well it works in treating participants
with ongoing EGFR inhibitor-induced rash?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve
EGFR inhibitor-induced rash. Epidermal growth factor receptor (EGFR) inhibitors have
been used to treat a variety of cancers, including head and neck cancer, non–small-cell
lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. Examples of drugs that
make up this class of targeted medications include cetuximab, panitumumab, necitumumab,
erlotinib, gefitinib, osimertinib, and afatinib. One of the most common side effects
of these drugs is skin reactions such as papulopustular (acneiform) rash. This study
is for people with EGFR inhibitor-induced rashes.
Study Reference #: UMLT18037
Lead Researcher (Principal Investigator)
Lead Researcher: Richard Dunne
Study Contact InformationStudy Coordinator: Nicholas Gerbino
Phone: (585) 273-2605
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search